drugset
drugset / Trial / NCT03576651

A Study to Compare the Pharmacokinetics of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers

NCT03576651 ↗

Phase 1 Completed 154 enrolled JHL Biotech, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase I, Double-blind, Randomized, Parallel-group, Single-dose, Three-Arm Study to Compare the Pharmacokinetics and to Evaluate the Tolerability, Safety and Immunogenicity of JHL1149 and Bevacizumab (Avastin) Sourced from the European Union (EU) and the Union States (US) in Healthy Male Volunteers

Timeline

Start
2018-03-24
Primary completion
2018-09-17
Completion
2019-12-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bevacizumab Monoclonal antibody 1 mg/kg Intravenous
Subject JHL1149 Unknown 1 mg/kg Intravenous

Indications

No indication recorded.